iRadimedIRMD
IRMD
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
209% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 11
63% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 40
14% more funds holding
Funds holding: 143 [Q3] → 163 (+20) [Q4]
12% more capital invested
Capital invested by funds: $340M [Q3] → $381M (+$40.8M) [Q4]
1.23% more ownership
Funds ownership: 53.47% [Q3] → 54.7% (+1.23%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
81% less call options, than puts
Call options by funds: $33K | Put options by funds: $176K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$72
36%
upside
Avg. target
$72
36%
upside
High target
$72
36%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Roth MKM Jason Wittes 43% 1-year accuracy 9 / 21 met price target | 36%upside $72 | Buy Reiterated | 14 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference
WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37 th Annual Roth Conference.

Neutral
Seeking Alpha
1 month ago
IRADIMED CORPORATION (IRMD) Q4 2024 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q4 2024 Earnings Conference Call February 13, 2025 11:00 AM ET Company Participants Roger Susi - Founder, President and CEO John Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Nelson Cox - Lake Street Capital Markets Operator Welcome to the IRADIMED CORPORATION Fourth Quarter of 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Negative
Zacks Investment Research
1 month ago
IRadimed (IRMD) Lags Q4 Earnings Estimates
IRadimed (IRMD) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.39 per share a year ago.

Neutral
GlobeNewsWire
2 months ago
IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025
WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

Neutral
GlobeNewsWire
2 months ago
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging compatible medical devices, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2024.

Positive
Zacks Investment Research
3 months ago
iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Neutral
GlobeNewsWire
3 months ago
IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference.

Positive
Zacks Investment Research
3 months ago
Here's Why Momentum in iRadimed (IRMD) Should Keep going
iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Neutral
GlobeNewsWire
3 months ago
IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025
WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), today announced it has been ranked 24th on Forbes' list of America's Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

Positive
Zacks Investment Research
4 months ago
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Charts implemented using Lightweight Charts™